Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Pacira BioSciences, Inc. has received a consensus rating of "Moderate Buy" from analysts, with five giving a buy rating and two rating it as hold.
• The stock has a 12-month price objective of approximately $30.83, and recent analysis indicated mixed responses from different research firms regarding price targets and ratings.
• In its latest quarterly earnings, Pacira reported an EPS of $0.74, exceeding estimates, but revenue was slightly below expectations with a year-over-year growth of 1.7%.

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $30.8333.

A number of analysts have recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Zacks Research upgraded shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 target price for the company in a research note on Friday, July 25th.

Insider Activity

In other news, Director Marcelo Bigal sold 4,912 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the sale, the director owned 11,393 shares in the company, valued at approximately $269,672.31. This trade represents a 30.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 6.40% of the company's stock.

Institutional Trading of Pacira BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming raised its stake in Pacira BioSciences by 8.0% in the 4th quarter. State of Wyoming now owns 6,566 shares of the company's stock worth $124,000 after purchasing an additional 487 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Pacira BioSciences by 17.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company's stock worth $84,000 after purchasing an additional 531 shares in the last quarter. US Bancorp DE raised its stake in Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock worth $56,000 after purchasing an additional 537 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Pacira BioSciences by 3.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after purchasing an additional 794 shares in the last quarter. Finally, Corton Capital Inc. raised its stake in Pacira BioSciences by 6.0% in the 4th quarter. Corton Capital Inc. now owns 21,575 shares of the company's stock worth $406,000 after purchasing an additional 1,214 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Stock Performance

Shares of PCRX traded down $0.28 during midday trading on Monday, reaching $26.45. The stock had a trading volume of 606,830 shares, compared to its average volume of 663,404. The firm has a 50 day simple moving average of $23.97 and a 200-day simple moving average of $24.59. Pacira BioSciences has a one year low of $12.61 and a one year high of $27.64. The firm has a market cap of $1.19 billion, a PE ratio of -9.51 and a beta of 0.42. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. The company had revenue of $181.10 million during the quarter, compared to the consensus estimate of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The company's quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.96 EPS. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Pacira BioSciences will post 2.41 EPS for the current year.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.